683 Capital Management »

Seres Therapeutics shares owned by 683 Capital Management

Quarter-by-quarter ownership of Seres Therapeutics (MCRB) shares owned by 683 Capital Management from 13F filings

Historical chart of 683 Capital Management investment in Seres Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Seres Therapeutics held by 683 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Seres Therapeutics by 683 Capital Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $778k 52k 14.88

More positions owned by 683 Capital Management

Palantir Technologies Cl A Put Option (PLTR)
Eli Lilly & Co. Put Option (LLY)
Capital One Financial (COF)
Tesla Motors Put Option (TSLA)
NVIDIA Corporation Put Option (NVDA)
Wave Life Sciences SHS (WVE)
Carvana Cl A (CVNA)
Madrigal Pharmaceuticals Put Option (MDGL)
Alnylam Pharmaceuticals (ALNY)
Praxis Precision Medicines I Com New Put Option (PRAX)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Protagonist Therapeutics (PTGX)
Gxo Logistics Incorporated Common Stock (GXO)
Hilton Grand Vacations (HGV)
Anaptysbio Inc Common (ANAB)

View all positions for 683 Capital Management

Top funds holding Seres Therapeutics

Flagship Ventures Management
Susquehanna International
Vanguard Group
Marshall Wace
BlackRock
Vontobel Holding
Geode Capital Management
Citadel Advisors
Caption Management
683 Capital Management
State Street Corporation
Lion Point Capital
Charles Schwab Investment Management
Jane Street
Schonfeld Strategic Advisors

View all funds holding Seres Therapeutics